For US residents only

Alprolix® [Coagulation Factor IX (Recombinant), Fc Fusion Protein] logo
Sign up now
Man with backpack outdoors (patient portrayal)

Benefits of ALPROLIX®
on demand

Man with backpack outdoors (patient portrayal)

Benefits of ALPROLIX®
on demand

Bleed control you can trust*

Just 1 infusion of ALPROLIX resolved most bleeds for adults, adolescents, and kids:

90%

of adults and adolescents aged 12 and older

B-LONG trial (n=575/636)

75%

of kids aged 1 to 11

 

Kids B-LONG trial (n=45/60)

87%

of previously untreated patients aged 0.1 to 2

PUPs B-LONG trial (n=74/85)

Most patients rated their response to the first infusion as good or excellent†

84%

of adults and adolescents aged 12 and older

B-LONG trial (n=513/613)

89%

of kids aged 1 to 11

 

Kids B-LONG trial (n=47/53)

91%

of previously untreated patients aged 0.1 to 2

PUPs B-LONG trial (n=72/79)

B-LONG was a phase 3 study that investigated the safety and efficacy of ALPROLIX in 123 previously treated adult and adolescent patients with severe hemophilia B. The study included a fixed-interval arm (n=63), a fixed-dose arm (n=29), an episodic arm (n=27), and a surgical arm (n=12).

Kids B-LONG was a phase 3 study that investigated the safety and efficacy of ALPROLIX in 30 previously treated pediatric patients with severe to moderately severe hemophilia B. 15 patients were 1 to 5 years of age; 15 patients were 6 to 11 years of age. All patients were treated with individualized prophylaxis.

The PUPs B-LONG study evaluated ALPROLIX efficacy and safety in 33 people <18 years old who had never used an infused factor IX product before, sometimes called previously untreated patients, or PUPs.
These children (range: 0.1 to 2 years) were studied in a prophylaxis arm (n=28) and an on-demand arm (n=5).
*ALPROLIX has been proven to help patients prevent bleeding episodes using a prophylaxis regimen.
7 first injections for bleeding episodes in children were not evaluated for response and are excluded from this analysis. Excellent response was defined as abrupt pain relief and/or improvement in signs of bleeding. Good response was defined as definite pain relief and/or improvement in signs of bleeding but possibly requiring another injection in 1 or 2 days.

Ready to switch from on demand to prophy?
ALPROLIX may help ease your transition

47% of people ≥12 years treated with ALPROLIX on demand during the B-LONG trial switched to ALPROLIX prophy during the B-YOND trial

Compared with on demand treatment, adults and adolescents on ALPROLIX prophy had fewer bleeds—and fewer infusions to resolve them

TODO
Studied in prophylaxis patients (n=29).
Learn more about bleed protection with ALPROLIX prophy
Learn more
Find your CoRe Manager and connect today
Sanofi Hemophilia Community Relations and Education (CoRe) Managers offer education and support to people living with hemophilia and their families, including treatment options and lifestyle tips. Use our CoRe Locator to find the CoRe Manager in your area.
Find my CoRe

Important Safety Information and Indication

Indication

ALPROLIX® [Coagulation Factor IX (Recombinant), Fc Fusion Protein] is an injectable medicine that is used to help control and prevent bleeding in people with hemophilia B. Hemophilia B is also called congenital Factor IX deficiency. Your healthcare provider may give you ALPROLIX when you have surgery.

Important Safety Information

Do not use ALPROLIX if you are allergic to ALPROLIX or any of the other ingredients in ALPROLIX.

Tell your healthcare provider if you have or have had any medical problems, take any medicines, including prescription and non-prescription medicines, supplements, or herbal medicines, have any allergies and all your medical conditions, including if you are pregnant or planning to become pregnant, are breastfeeding, or have been told you have inhibitors (antibodies) to Factor IX.

Common side effects of ALPROLIX include headache, abnormal sensation in the mouth, and pain in your side with blood in your urine, which may be a sign of clot formation in the urinary collecting system.

Allergic reactions may occur with ALPROLIX. Call your healthcare provider or get emergency treatment right away if you have any of the following symptoms: hives, chest tightness, wheezing, difficulty breathing, or swelling of the face.

Redness to the skin at the injection site may also occur.

ALPROLIX may increase the risk of formation of abnormal blood clots in your body, especially if you have risk factors for developing blood clots. Call your healthcare provider or seek emergency care if you have symptoms of a possible abnormal blood clot, which may include: chest pain, difficulty breathing, unexpected swelling of an arm or leg with or without pain or tenderness.

Your body can also make antibodies called "inhibitors" against ALPROLIX, which may stop ALPROLIX from working properly.

These are not all of the possible side effects of ALPROLIX. Talk to your healthcare provider right away about any side effect that bothers you or does not go away, or if bleeding is not controlled using ALPROLIX.
© 2024 Sanofi. All rights reserved. ALPROLIX and Sanofi are registered trademarks of Sanofi or an affiliate. All other trademarks are the property of their respective owners. MAT-US-2021804-V8.0-10/2024 Last updated: October 2024